SpyGlass Pharma Inc
spyglasspharma.comWhat Do They Do?
Develops sustained-release drug-delivery systems for chronic eye conditions, including a bimatoprost implant attached to an artificial lens for people with glaucoma or ocular hypertension.
10-K for FY2025, filed Mar 26, 2026We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye…View ↗
Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our…View ↗
We believe our novel drug delivery technology (the SpyGlass Platform) has the potential to significantly improve the lives of patients with…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$19.9MView ↗
- ▲ +129% (Loss)
- vs −$8.7M in Q2 FY2025
Who Do They Compete With?
Competes with Alcon, Allergan, Bausch & Lomb, Glaukos, Johnson & Johnson, Astellas, Genentech, and Regeneron
10-K for FY2025, filed Mar 26, 2026Our lead product candidate, the BIM-IOL System, is designed to treat OAG and OHT, placing us in direct competition with a range of…View ↗
Loading...
